SUBSCRIBE
SUBSCRIBE

Denali Therapeutics Inc.

NEWS
Business
The Next Generation: Top 20 Life Science Startups to Watch in 2017
BioSpace is proud to present its NextGen “Class of 2017,” which is a list of 20 up-and-coming life science companies that launched no earlier than 2014.
January 3, 2017
 · 
11 min read
 · 
Mark Terry
What You Need to Know About Denali Therapeutics
Business
What You Need to Know About Denali
January 3, 2017
 · 
4 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Business
Led by Former Genentech Execs, Denali Banks $130 Million, Initiates Trial and Announces a Handful of Partnerships
August 25, 2016
 · 
3 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Biotech Bay
Nine Bay Area Biotechs Vie to be the “Next Genentech”
May 24, 2016
 · 
4 min read
Business
Inside the $50 Billion Biotech Sugar Daddy that Invested in Startups Like Denali, Juno
March 3, 2016
 · 
3 min read
Job Trends
Denali, Helmed by Former Genentech Execs, Takes Space in South San Francisco Site
January 18, 2016
 · 
2 min read
Business
Pfizer Board Member Jumps Ship to $217 Million Startup Denali
May 21, 2015
 · 
3 min read
Biotech Bay
Why Denali Raised A $217 Million Financing Round: Not Just “Because It Could”
May 21, 2015
 · 
1 min read
Load More
AWARDS
  • NextGen Class of 2017
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Drug Development
Denali Therapeutics Announces Positive Interim Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with the Lysosomal Storage Disease Hunter Syndrome (MPS II)
July 25, 2021
 · 
12 min read
Biotech Bay
Denali Therapeutics to Present Interim Data from Phase 1/2 Study of ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at MPS 2021Management to host webinar for analysts and investors on July 25th
July 15, 2021
 · 
5 min read
Drug Development
Denali Therapeutics Announces Initiation of Phase 2 Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in Cutaneous Lupus Erythematosus (CLE) Patients
June 28, 2021
 · 
5 min read
Business
Denali Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
May 3, 2021
 · 
12 min read
Drug Development
Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage Development Plans in Parkinson’s Disease
May 1, 2021
 · 
9 min read
Biotech Bay
Denali Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment of Patients with Hunter Syndrome (MPS II)
March 11, 2021
 · 
7 min read
Business
Denali Therapeutics Reports Full Year 2020 Financial Results and Business Highlights
February 25, 2021
 · 
15 min read
Biotech Bay
Denali Therapeutics Reports Positive Three-Month Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with Hunter Syndrome (MPS II)
February 12, 2021
 · 
10 min read
Biotech Bay
Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium™– Management to host webinar for analysts on Friday, Feb. 12, at 8:00 a.m. Eastern Time –
February 5, 2021
 · 
3 min read
Business
Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors
January 11, 2021
 · 
2 min read
Load More